DISCLOSURES
Gabrielle Marie Rivin BA MD has no conflicts of interest to disclose. Alan Fleischer MD is a consultant for Boerhringer-Ingelheim, Incyte, Qurient, SCM Lifescience, Syneos, and Trevi. He is an investigator for Galderma and Trevi.
REFERENCES
- Collier EK, Parvataneni RK, Lowes MA, et al. Diagnosis and management of hidradenitis suppurativa in women. Am J Obstet Gynecol. 2021;224(1):54- 61. doi:10.1016/j.ajog.2020.09.036
- Adelekun AA, Villa NM, Hsiao JL, et al. Pregnancy in hidradenitis suppurativa—patient perspectives and practice gaps. JAMA Dermatology. 2021;157(2):227-230. doi:10.1001/jamadermatol.2020.5162
- Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med. 2016;374(9):843-852. doi:10.1056/nejmsa1506575
- Collier EK, Seivright JR, Shi VY, et al. Pregnancy and breastfeeding in hidradenitis suppurativa: a review of medication safety. Dermatol Ther. 2021;34(1). doi:10.1111/dth.14674
- Matok I, Gorodischer R, Koren G, et al. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations. Br J Clin Pharmacol. 2009;68(6):956-962. doi:10.1111/j.1365-2125.2009.03544.x
- Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91-101. doi:10.1016/j.jaad.2019.02.068
- J Am Acad Dermatol. 2019;81(1):91-101. doi:10.1016/j.jaad.2019.02.068
AUTHOR CORRESPONDENCE
Gabrielle Marie Rivin BA MD peckgl@mail.uc.edu
